Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain

2024-04-09 17:47:03


EQS Newswire / 09/04/2024 / 17:47 UTC+8

WizMediBio Signs Contract with the Wisconsin Alumni Research Foundation (WARF) for Botulinum Toxin Strain

 

Seoul, Korea - April 09, 2024 - (SeaPRwire) - WizMedi Bio Co., Ltd. (WizMedi Bio) today announced that it has reached a formal agreement with the Wisconsin Alumni Research Foundation (WARF), established by the University of Wisconsin, for the patent and technical licensing of the A6 botulinum neurotoxin strain. This agreement enables WizMedi Bio to prove the origin of the strain, which has been the primary hurdle to the botulinum toxin business, and paves a pathway to develop a stable new business in the market.

fncls.ssp?fn=download2_file&code_str=038ebe4007286acb4ea9c99467d8b564

The A1 botulinum toxin currently dominates the market and as a novel subtype, A6 presents itself as a challenger. Therefore, the future course of the A6 strain as a BOTULINUM TOXIN provides a new opportunity in the botulinum field. According to research published by Dr. Eric A. Johnson and colleagues, the A6 strain is known to have high potency and long duration of action in animal models. Evidence indicates the toxin is also known to stay long in local areas. Due to its high potency with fewer side effects, the A6 strain is expected to bring a new perspective to the market.

WizMedi Bio has signed consulting agreements with world-renowned scholars in this field and announced that it will actively target not only the Korean domestic market but also the U.S. market, which is a challenging market to enter. To bring A6 to commerce, the company has also signed an agreement for a strategic alliance with BNC Korea, Inc. (http://bnckorea.co.kr/), utilizing their GMP botulinum toxin facility, for joint research and development. Moreover, the company will actively work in tandem with the FDA to secure a production facility in the U.S.

WizMedi Bio was co-founded by two medical doctors based on their expertise and know-how gained at WizMedi Co., Ltd., a company dedicated to the research and development of products targeted at the beauty and medical aesthetic markets. The company aims to capture the botulinum toxin market based on maximized utilization of its distribution network and experience. In particular, it will actively target the U.S. market, which accounts for more than 60% of the global market.

"We will enhance the global market, especially the U.S., with novel botulinum toxin products," said Choi Yong-hoon, the CEO of WizMedi Bio.

Social Links

Twitter: https://twitter.com/WIZMEDIKR

Media Contact

Company: Wizmedi Co., Ltd.

Contact: Media Team

Email: wizmedisales@wizmedi.kr

Website: https://wizmedi.kr

SOURCE: Wizmedi Co., Ltd.

09/04/2024 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

fncls.ssp?fn=show_t_gif&application_id=1876569&application_name=news&site_id=todayir~~~8718cfbc-9d37-4155-9f28-3af0e96374d5

Link

EQS Group

2024-05-20
14:30:44
SeaPRwire Unveils Innovative Forex Trading Press Release Distribution Solution for Southeast Asia
2024-05-14
09:11:22
TJI (Stock code 2217) Announces FY2024 Annual Results
2024-05-13
17:34:57
Enegix Global opens new office in Brazil to expand its operations
10:10:58
The Power of RaffAello - Transforming the Investment Landscape
2024-05-07
14:45:08
Polymetal International plc: Q1 2024 production results
2024-05-02
10:33:28
Macau Pass Won the “Best Cash Management Solution” award at The Asset Triple A Treasurise Awards 2024, Leading Innovation in Cross-Bank Automated Merchant Fund Settlement
2024-05-01
09:00:04
Key Performance Indicators Speak for Themselves GCL Technology Publishes the ESG Report, Verified for the First Time by SGS  
2024-04-29
17:55:08
PetroChina Kicked Off Q1 2024 With High-Quality and Profitable Growth
16:34:59
Jefferies Reiterates “Buy” Rating on Modern Dental (03600.HK) with HK$8.50 Target Price  
2024-04-28
20:40:16
【Press Release】Sinopec Corp. Announces 2024 Q1 Results
11:33:32
Leading A New Trend in the Tourism Industry, Macau Pass' 'mPass Travel' Debuts at the Macau International Travel Expo
2024-04-26
13:17:21
【Press Release】China XLX Announces 2024 1Q Results
2024-04-25
09:00:11
China New Higher Education Group Limited Focusing on High-quality Development Continuously, Talent Cultivation and High-quality Employment Achieved Fruitful Results
2024-04-24
20:33:59
Newborn Town Q1 2024 Revenue Expected to Exceed RMB 1,000 Million as Social Networking Business Records Over 65% YoY Growth
2024-04-20
12:00:10
Chow Tai Fook Jewellery Group Shines on Global Stage with Paris 100 Sponsorship, Promoting Chinese Craftsmanship to Celebrate 95 Years of Heritage
2024-04-19
17:23:54
PaySaxas Unveils International Invoices Solution, Mastering Cross-Border Payments
2024-04-18
14:49:23
Chow Tai Fook Jewellery Celebrates 95-Year Anniversary and Embarks on Brand Transformation Journey
2024-04-15
09:00:05
Trio Industrial Electronics Group Limited Announces 2023 Annual Results
2024-04-12
17:36:38
Chow Tai Fook Jewellery Group Announces 4QFY2024 Quarterly Results
2024-04-10
17:58:47
Airdoc Technology (02251.HK) achieved remarkable success in 2023, accelerating its commercialization in an unparalleled way  
Back to Top